CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 30, 2015
Result type: Reports
Project Number: SR0459-000
Product Line: Reimbursement Review

Generic Name: Teduglutide

Brand Name: Revestive

Manufacturer: Shire Pharma Canada ULC/NPS Pharma Holdings Limited

Therapeutic Area: Short bowel syndrome

Indications: Short Bowel Syndrome (SBS)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 27, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions